CA 27-29 in patients with breast cancer with pulmonary fibrosis.

A series of 4 patients with breast cancer who have persistent elevation in CA 27.29 are reported, finding that false-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Cancer antigen (CA) 27-29, which is expressed on most carcinoma cells, is a soluble form of glycoprotein MUC1. It is overexpressed in tumors involving glandular epithelial cells, such as breast tumors. Measurement of CA 27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer. Although serial determination of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of approximately 2-9 months, the clinical value of this lead time remains to be determined. False-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Herein, we report a series of 4 patients with breast cancer (2 patients with interstitial lung fibrosis and 2 patients with nonspecific fibrotic lung changes) who have persistent elevation in CA 27.29 (normal, <38 U/mL).

Tumor Markers for Breast Cancer: Benefits, Drawbacks, Results & More

Chest CT Diagnosis and Clinical Management of Drug-related

Dr. Sobha Kurian, MD – Morgantown, WV

miR-29s function as tumor suppressors in gliomas by targeting TRAF4 and predict patient prognosis

Construction and validation of an immunity-related prognostic signature for breast cancer

Pneumonitis and pulmonary fibrosis associated with breast cancer

IJMS, Free Full-Text

CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis

Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society

miR-29s function as tumor suppressors in gliomas by targeting

Characteristics of advanced fibrosis in usual interstitial